Glecirasib is intended for the treatment of pancreatic cancer patients with the KRAS G12C mutation. Credit: Nemes Laszlo/Shutterstock.com.

Jacobio Pharma has received breakthrough therapy designation (BTD) for glecirasib to treat pancreatic cancer patients with the KRAS G12C mutation.

The company’s in-house KRAS G12C inhibitor received the designation from the Center for Drug Evaluation of China’s National Medical Products Administration.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The BTD has been granted based on the results from an ongoing pivotal, multi-centre, single-arm, open-label study that assessed the safety and efficacy of the single agent glecirasib.

Patients with KRAS G12C-mutated locally advanced or metastatic pancreatic cancer who progressed on frontline standard care treatment were enrolled in the trial.

In December 2022, glecirasib received the first BTD for treating advanced or metastatic non-small cell lung cancer (NSCLC) patients with the KRAS G12C mutation.

See Also:

Jacobio is also currently conducting a pivotal Phase I/II monotherapy study in China evaluating glecirasib in STK11 [a germline mutation] co-mutated NSCLC patients in the front-line setting.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Combination therapy trials of glecirasib with SHP2 inhibitor JAB-3312 to treat NSCLC and with Cetuximab for colorectal cancer are also being carried out in the country.

Other Phase I/II clinical trials of glecirasib are ongoing in Europe and the US for treating patients with advanced solid tumours harbouring the KRAS G12C mutation.

The company also develops new molecules that target immune checkpoints, tumour metabolism and P53, RB and MYC-signalling pathways.